OpenAccessBelV2, PascalFrancis, Corpus, bibRecord, 000085

The Financial Burden of Rotavirus Disease in Four Countries of the European Union

Identifieur interne : 000085 ( PascalFrancis/Corpus ); précédent : 000084; suivant : 000086

The Financial Burden of Rotavirus Disease in Four Countries of the European Union

Auteurs : Baudouin Standaert ; Olof Harlin ; Ulrich Desselberger

Source :

The Pediatric infectious disease journal [ 0891-3668 ] ; 2008.

RBID : Pascal:08-0129053

Descripteurs français

Pascal (Inist)
- Infection, Europe, Coût, Pédiatrie, Rotavirus, Gastroentérite virale.

English descriptors

KwdEn :
- Costs, Europe, Infection, Pediatrics, Rotavirus, Viral gastroenteritis.

Abstract

Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0891-3668`
A02	`01`			`@0 PIDJEV`
A03		`1`		`@0 Pediatr. infect. dis. j.`
A05				`@2 27`
A06				`@2 1 @3 SUP`
A08	`01`	`1`	`ENG`	`@1 The Financial Burden of Rotavirus Disease in Four Countries of the European Union`
A09	`01`	`1`	`ENG`	`@1 Rotavirus: Evidence for vaccination`
A11	`01`	`1`		`@1 STANDAERT (Baudouin)`
A11	`02`	`1`		`@1 HARLIN (Olof)`
A11	`03`	`1`		`@1 DESSELBERGER (Ulrich)`
A12	`01`	`1`		`@1 LEPAGE (Philippe) @9 ed.`
A14	`01`			`@1 GlaxoSmithKline Biologicals @2 Wavre @3 BEL @Z 1 aut.`
A14	`02`			`@1 archimed medical communication AG @2 Zofingen @3 CHE @Z 2 aut.`
A14	`03`			`@1 Department of Medicine, University of Cambridge @2 Cambridge @3 GBR @Z 3 aut.`
A15	`01`			`@1 Université libre de Bruxelles @2 Brussels @3 BEL @Z 1 aut.`
A20				`@2 S20-S27`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20356 @5 354000162722140030`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 46 ref.`
A47	`01`	`1`		`@0 08-0129053`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The Pediatric infectious disease journal`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.
C02	`01`	`X`		`@0 002B05C02F`
C03	`01`	`X`	`FRE`	`@0 Infection @5 01`
C03	`01`	`X`	`ENG`	`@0 Infection @5 01`
C03	`01`	`X`	`SPA`	`@0 Infección @5 01`
C03	`02`	`X`	`FRE`	`@0 Europe @2 NG @5 07`
C03	`02`	`X`	`ENG`	`@0 Europe @2 NG @5 07`
C03	`02`	`X`	`SPA`	`@0 Europa @2 NG @5 07`
C03	`03`	`X`	`FRE`	`@0 Coût @5 08`
C03	`03`	`X`	`ENG`	`@0 Costs @5 08`
C03	`03`	`X`	`SPA`	`@0 Coste @5 08`
C03	`04`	`X`	`FRE`	`@0 Pédiatrie @5 09`
C03	`04`	`X`	`ENG`	`@0 Pediatrics @5 09`
C03	`04`	`X`	`SPA`	`@0 Pediatría @5 09`
C03	`05`	`X`	`FRE`	`@0 Rotavirus @2 NW @5 10`
C03	`05`	`X`	`ENG`	`@0 Rotavirus @2 NW @5 10`
C03	`05`	`X`	`SPA`	`@0 Rotavirus @2 NW @5 10`
C03	`06`	`X`	`FRE`	`@0 Gastroentérite virale @4 CD @5 96`
C03	`06`	`X`	`ENG`	`@0 Viral gastroenteritis @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Reoviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Reoviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Reoviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`02`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`02`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'intestin @5 37`
C07	`03`	`X`	`ENG`	`@0 Intestinal disease @5 37`
C07	`03`	`X`	`SPA`	`@0 Intestino patología @5 37`
C07	`04`	`X`	`FRE`	`@0 Economie santé @5 38`
C07	`04`	`X`	`ENG`	`@0 Health economy @5 38`
C07	`04`	`X`	`SPA`	`@0 Economía salud @5 38`
C07	`05`	`X`	`FRE`	`@0 Pathologie de l'appareil digestif @5 39`
C07	`05`	`X`	`ENG`	`@0 Digestive diseases @5 39`
C07	`05`	`X`	`SPA`	`@0 Aparato digestivo patología @5 39`
C07	`06`	`X`	`FRE`	`@0 Santé publique @5 40`
C07	`06`	`X`	`ENG`	`@0 Public health @5 40`
C07	`06`	`X`	`SPA`	`@0 Salud pública @5 40`
N21				`@1 077`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0129053 INIST
ET :	The Financial Burden of Rotavirus Disease in Four Countries of the European Union
AU :	STANDAERT (Baudouin); HARLIN (Olof); DESSELBERGER (Ulrich); LEPAGE (Philippe)
AF :	GlaxoSmithKline Biologicals/Wavre/Belgique (1 aut.); archimed medical communication AG/Zofingen/Suisse (2 aut.); Department of Medicine, University of Cambridge/Cambridge/Royaume-Uni (3 aut.); Université libre de Bruxelles/Brussels/Belgique (1 aut.)
DT :	Publication en série; Niveau analytique
SO :	The Pediatric infectious disease journal; ISSN 0891-3668; Coden PIDJEV; Etats-Unis; Da. 2008; Vol. 27; No. 1 SUP; S20-S27; Bibl. 46 ref.
LA :	Anglais
EA :	Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.
CC :	002B05C02F
FD :	Infection; Europe; Coût; Pédiatrie; Rotavirus; Gastroentérite virale
FG :	Reoviridae; Virus; Pathologie de l'intestin; Economie santé; Pathologie de l'appareil digestif; Santé publique
ED :	Infection; Europe; Costs; Pediatrics; Rotavirus; Viral gastroenteritis
EG :	Reoviridae; Virus; Intestinal disease; Health economy; Digestive diseases; Public health
SD :	Infección; Europa; Coste; Pediatría; Rotavirus
LO :	INIST-20356.354000162722140030
ID :	08-0129053

Links to Exploration step

Pascal:08-0129053

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Financial Burden of Rotavirus Disease in Four Countries of the European Union</title>
<author><name sortKey="Standaert, Baudouin" sort="Standaert, Baudouin" uniqKey="Standaert B" first="Baudouin" last="Standaert">Baudouin Standaert</name>
<affiliation><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals</s1>
<s2>Wavre</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harlin, Olof" sort="Harlin, Olof" uniqKey="Harlin O" first="Olof" last="Harlin">Olof Harlin</name>
<affiliation><inist:fA14 i1="02"><s1>archimed medical communication AG</s1>
<s2>Zofingen</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Desselberger, Ulrich" sort="Desselberger, Ulrich" uniqKey="Desselberger U" first="Ulrich" last="Desselberger">Ulrich Desselberger</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Medicine, University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0129053</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0129053 INIST</idno>
<idno type="RBID">Pascal:08-0129053</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000085</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Financial Burden of Rotavirus Disease in Four Countries of the European Union</title>
<author><name sortKey="Standaert, Baudouin" sort="Standaert, Baudouin" uniqKey="Standaert B" first="Baudouin" last="Standaert">Baudouin Standaert</name>
<affiliation><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals</s1>
<s2>Wavre</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harlin, Olof" sort="Harlin, Olof" uniqKey="Harlin O" first="Olof" last="Harlin">Olof Harlin</name>
<affiliation><inist:fA14 i1="02"><s1>archimed medical communication AG</s1>
<s2>Zofingen</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Desselberger, Ulrich" sort="Desselberger, Ulrich" uniqKey="Desselberger U" first="Ulrich" last="Desselberger">Ulrich Desselberger</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Medicine, University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Pediatric infectious disease journal</title>
<title level="j" type="abbreviated">Pediatr. infect. dis. j.</title>
<idno type="ISSN">0891-3668</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Pediatric infectious disease journal</title>
<title level="j" type="abbreviated">Pediatr. infect. dis. j.</title>
<idno type="ISSN">0891-3668</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Costs</term>
<term>Europe</term>
<term>Infection</term>
<term>Pediatrics</term>
<term>Rotavirus</term>
<term>Viral gastroenteritis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Infection</term>
<term>Europe</term>
<term>Coût</term>
<term>Pédiatrie</term>
<term>Rotavirus</term>
<term>Gastroentérite virale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0891-3668</s0>
</fA01>
<fA02 i1="01"><s0>PIDJEV</s0>
</fA02>
<fA03 i2="1"><s0>Pediatr. infect. dis. j.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>1</s2>
<s3>SUP</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The Financial Burden of Rotavirus Disease in Four Countries of the European Union</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Rotavirus: Evidence for vaccination</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>STANDAERT (Baudouin)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HARLIN (Olof)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DESSELBERGER (Ulrich)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>LEPAGE (Philippe)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>GlaxoSmithKline Biologicals</s1>
<s2>Wavre</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>archimed medical communication AG</s1>
<s2>Zofingen</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Medicine, University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Université libre de Bruxelles</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA20><s2>S20-S27</s2>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20356</s2>
<s5>354000162722140030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>46 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0129053</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Pediatric infectious disease journal</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05C02F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Infection</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Infection</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Infección</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Coût</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Costs</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Coste</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pédiatrie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Pediatrics</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Pediatría</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Rotavirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Rotavirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Rotavirus</s0>
<s2>NW</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Gastroentérite virale</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Viral gastroenteritis</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Reoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Reoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Reoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'intestin</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Intestinal disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Intestino patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Economie santé</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Health economy</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Economía salud</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Public health</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>40</s5>
</fC07>
<fN21><s1>077</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0129053 INIST</NO>
<ET>The Financial Burden of Rotavirus Disease in Four Countries of the European Union</ET>
<AU>STANDAERT (Baudouin); HARLIN (Olof); DESSELBERGER (Ulrich); LEPAGE (Philippe)</AU>
<AF>GlaxoSmithKline Biologicals/Wavre/Belgique (1 aut.); archimed medical communication AG/Zofingen/Suisse (2 aut.); Department of Medicine, University of Cambridge/Cambridge/Royaume-Uni (3 aut.); Université libre de Bruxelles/Brussels/Belgique (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The Pediatric infectious disease journal; ISSN 0891-3668; Coden PIDJEV; Etats-Unis; Da. 2008; Vol. 27; No. 1 SUP; S20-S27; Bibl. 46 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Rotavirus disease is associated with a substantial financial burden. Rotavirus gastroenteritis in children under 5 results in considerable medical resource utilization and burden for parents and society. Methods: For this study a modeling approach was employed to assess the financial burden ofrotavirus disease in 4 European Union countries (Belgium, France, the Netherlands, and the United Kingdom). Both direct medical costs to health authorities and indirect costs borne by society, parents, and employers were calculated. Results: The Purchasing-Power-Parity-adjusted direct cost expressed as a cost per exposure year, per child under 5, was highest in France (∈12.26) and Belgium (∈11.80) compared with the Netherlands (∈8.13) and the United Kingdom (∈7.67). The Purchasing-Power-Parity-adjusted indirect cost was estimated to be highest in the United Kingdom (∈15.47) and the Netherlands (∈15.33) compared with France (∈11.31) and Belgium (∈10.24). The sum of the direct medical and indirect costs of rotavirus disease management was estimated to be ∈23.11 ± ∈0.70/yr per child under 5 years for all 4 countries. Conclusions: In countries where more emphasis was placed on first-line intervention (United Kingdom, the Netherlands), direct costs were lower than in countries where access to second-line healthcare support was more open (Belgium, France). The data suggest that the greater burden of financial responsibility of managing rotavirus disease in children was borne by society (higher in the United Kingdom and the Netherlands than in France and Belgium). In Europe investment in rotavirus disease management is substantial, therefore the medical and economic benefits of a vaccination strategy should be considered to reduce the medical and financial burden associated with acute rotavirus gastroenteritis.</EA>
<CC>002B05C02F</CC>
<FD>Infection; Europe; Coût; Pédiatrie; Rotavirus; Gastroentérite virale</FD>
<FG>Reoviridae; Virus; Pathologie de l'intestin; Economie santé; Pathologie de l'appareil digestif; Santé publique</FG>
<ED>Infection; Europe; Costs; Pediatrics; Rotavirus; Viral gastroenteritis</ED>
<EG>Reoviridae; Virus; Intestinal disease; Health economy; Digestive diseases; Public health</EG>
<SD>Infección; Europa; Coste; Pediatría; Rotavirus</SD>
<LO>INIST-20356.354000162722140030</LO>
<ID>08-0129053</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000085 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000085 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0129053
   |texte=   The Financial Burden of Rotavirus Disease in Four Countries of the European Union
}}

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024

	Serveur d'exploration autour du libre accès en Belgique
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour du libre accès en Belgique

The Financial Burden of Rotavirus Disease in Four Countries of the European Union

The Financial Burden of Rotavirus Disease in Four Countries of the European Union

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri